Déjà vu all over again: a recurrent flaw in anticoagulant study design

Research output: Contribution to journalReview articlepeer-review

Abstract

The availability of direct oral anticoagulants rapidly changed the landscape of anticoagulation between 2010 and the present. Randomized controlled trials demonstrating efficacy with similar or superior safety compared with warfarin led to the widespread use of direct oral anticoagulants in male and female patients of all ages. Years later, postmarketing data demonstrated a markedly increased rate of heavy menstrual bleeding (HMB) with rivaroxaban that had gone undetected in registry trials. Factor (F)XI inhibitors are currently being investigated as another alternative to available anticoagulation agents. While generally mild, the phenotype of inherited FXI deficiency includes bleeding in tissues with enhanced fibrinolysis, including HMB. Thus, we aimed to perform a systematic review of published studies on FXI inhibitors in order to estimate rates of HMB. However, we found that few studies included menstruating individuals, and even fewer specifically reported on uterine bleeding, highlighting once again a flaw in our approach to conducting trials of new anticoagulants.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalJournal of Thrombosis and Haemostasis
Volume23
Issue number1
DOIs
StatePublished - Jan 2025

Keywords

  • anticoagulant agents
  • clinical trials
  • menorrhagia
  • menstruation
  • randomized
  • uterine bleeding

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Déjà vu all over again: a recurrent flaw in anticoagulant study design'. Together they form a unique fingerprint.

Cite this